On the other hand, the anti-oncogenic effect of statins in HCV patients is less evident, probably due to modification of metabolic syndrome, insulin-mediated cell proliferation, and obesity-associated inflammation [33,38]. This evidence concerns the gene INS and metabolic syndrome.